NVG-291

NervGen Cleared to Enroll 2nd MAD Group in NVG-291 Trial

NervGen Pharma has been cleared to enroll a second group of healthy volunteers into the multiple ascending dose portion of its Phase 1 clinical trial of NVG-291, a therapeutic candidate for multiple sclerosis (MS). The trial’s Safety Review Committee approved the second group after seeing promising safety data…

NervGen Brings Advanced Imaging to Planned NVG-291 Trials

A partnership will allowĀ NervGen to use Imeka‘s proprietary biomarker imaging technology to precisely measure changes in the brain and spinal cord in its upcoming clinical trials, including a study ofĀ NVG-291 in people with multiple sclerosis (MS) NervGen plans to initiate Phase 1b/2Ā trials intoĀ its lead candidate for neural…

NervGen to Advance NVG-291 as Potential Remyelination Therapy for MS

NervGen wants to advance the development of NVG-291, its lead investigational therapy for spinal cord damage, as a potential remyelination treatment for multiple sclerosis (MS), the company announced. Following preclinical data showing that NVG-291 promotes myelin repair and regeneration of damaged nerves in animal models of…